Plain-English translation of NCT05517655 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Cystic Fibrosis research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing whether a special type of MRI scan (called 129-xenon MRI) can better detect how Trikafta, a new triple-combination cystic fibrosis medication, is working in young children. Instead of relying only on traditional breathing tests, researchers want to see if these detailed images of the lungs, liver, and pancreas can show treatment benefits more clearly and earlier—without exposing children to any radiation.
As this medication is now being given to younger children with milder cystic fibrosis symptoms, doctors need better ways to measure whether it's truly helping. Standard breathing tests may not be sensitive enough to catch early improvements, so researchers are testing whether advanced imaging can provide a clearer picture of how the treatment is working in multiple organs over time.
You likely qualify if…
You likely don't qualify if…
You will have two MRI visits: one before your child starts the new medication and one after beginning treatment. During each visit, your child will undergo a 129-xenon MRI scan of the lungs, liver, and pancreas—a painless imaging procedure that takes about 30–60 minutes. There are no needles or radiation involved. The study team will compare the before-and-after images to see whether the medication is producing measurable changes in organ health.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States